Elinor
Elinor Axlerod, Kfar-Sirkin IL
Patent application number | Description | Published |
---|---|---|
20130203383 | VERIFIED CHECK-IN - An embodiment of the invention provides a check-in verification system (VCS) that verifies a check-in by a user using a smartphone to check-in at a venue, by verifying that a geolocation provided by the smartphone agrees with a location of the venue and that a password used by the user and the venue are the same. | 08-08-2013 |
Elinor Briner-Goldstein, Ness-Ziona IL
Patent application number | Description | Published |
---|---|---|
20130045933 | ALOE-EMODIN DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER - The present invention relates to anthracycline derivatives that are based on an Aloe-emodin (AE) backbone attached to a glycoside (an amino sugar or amino carba-sugar). These derivatives are useful as chemotherapeutic agents. Advantageously, these derivatives are potent cytotoxic agents against a variety of anthracycline-resistant tumors. In addition, they may have reduced cardiotoxicity. As such, the novel compounds of the invention offer an advantage over currently available drugs. The present invention further relates to methods for preparing the novel Aloe-Emodin Glycoside (AEG) based derivatives, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers. | 02-21-2013 |
Elinor Dehan, New York, NY US
Patent application number | Description | Published |
---|---|---|
20090318535 | BETA -TrCP1, BETA -TrCP2 AND RSK1 OR RSK2 INHIBITORS AND METHODS FOR SENSITIZING TARGET CELLS TO APOPTOSIS - The invention relates to modulating BimEL levels (Bcl-2-Interacting Mediator of cell death, Extra Long isoform) to sensitize cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to increasing BimEL levels. In certain embodiments, the invention relates to inhibitors of at least one of β-TrCP1/2 or RSK1/2 proteins that sensitize tumor cells to chemotherapy-induced death or apoptosis. Additionally, the invention relates to cancer therapies, diagnostics, and methods for identifying novel drugs or drug candidates for increasing BimEL levels. | 12-24-2009 |
Elinor Karlsson, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150211067 | NEUROPSYCHIATRIC DISORDER-ASSOCIATED MUTATIONS AND USES THEREOF - Provided herein are methods and compositions for identifying subjects as having an elevated risk of developing or having a neuropsychiatric disorder. These subjects are identified based on the presence of one or more mutations. | 07-30-2015 |